Strategies for management and treatment of dyslipidemia in HIV/AIDS

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 18, Issue 2, 2006, Pages 149-157

  Sax, P E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATORVASTATIN; DELAVIRDINE; EFAVIRENZ; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; LOPINAVIR PLUS RITONAVIR; MEVINOLIN; NELFINAVIR; NEVIRAPINE; NICOTINIC ACID; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSUVASTATIN; SAQUINAVIR; SIMVASTATIN; STAVUDINE; UNINDEXED DRUG;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALCOHOL CONSUMPTION; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DYSLIPIDEMIA; ERUCTATION; EXERCISE; FLUSHING; HEART INFARCTION; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE; LIPID METABOLISM; LIPODYSTROPHY; LIVER TOXICITY; LOW FAT DIET; MEDLINE; MYOPATHY; PRIORITY JOURNAL; RHABDOMYOLYSIS; SIDE EFFECT; SMOKING CESSATION; SURVIVAL RATE; WEIGHT GAIN;

ANTILIPEMIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; CLOFIBRIC ACID; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; RISK REDUCTION BEHAVIOR;

EID: 28844458004     PISSN: 09540121     EISSN: None     Source Type: Journal    
DOI: 10.1080/09540120500161843     Document Type: Article

References (66)

1. Acevedo, M., Sprecher, D.L., Calabrese, L., Pearce, G.L., Coyner, D.L., Halliburton, S.S., et al. (2002). Pilot study of coronary atherosclerotic risk and plaque burden in HIV patients: A call for cardiovascular prevention. Atherosclerosis, 163, 349-354.
2. Allan, D.A., & Behrman, A.J. (2001). Lipid abnormalities in a healthcare worker receiving HIV prophylaxis. International Journal of STD and AIDS, 12, 532-534.
3. Amacher, D.E., Beck, R., Schomaker, S.J., & Kenny, C.V. (1997). Hepatic microsomal enzyme induction, beta-oxidation and cell proliferation following administration of clofibrate, gemfibrozil or bezafibrate in the CD rat. Toxicology and Applied Pharmacology, 142, 143-150.
4. Barrios, A., Blanco, F., García-Benayas, T., Gómez-Viera, J.M., de la Cruz, J.J., Soriano, V., et al. (2002). Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia. AIDS, 16, 2079-2081.
5. Bermingham, R.P., Whitsitt, T.B., Smart, M.L., Nowak, D.P., & Scalley, R.D. (2000). Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil. American Journal of Health-System Pharmacy, 57, 461-464.
6. Bonnet, F., Bonarek, M., de Witte, S., Beylot, J., & Morlat, P. (2002). Efavirenz-associated severe hyperlipidemia. Clinical Infectious Diseases, 35, 776-777.
7. Bozzette, S.A., Ake, C.F., Tam, H.K., Chang, S.W., & Louis, T.A. (2003). Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. New England Journal of Medicine, 348, 702-710.
8. Calza, L., Manfredi, R., Farneti, B., & Chiodo, F. (2003). Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy. International Journal of Antimicrobial Agents, 22, 54-59.
9. Carr, A., Thorisdottir, A., Samaras, K., Kaufmann, G.R., Chisholm, D.J., & Cooper, D.A. (1999). Reversibility of protease inhibitor (PI) lipodystrophy syndrome on stopping PIs or switching to nelfinavir [abstract 668]. Available at:http://www.retroconference.org/99/abstracts/668.htm
10. Currier, J., Taylor, A., Boyd, F., Kawabata, H., Maa, J., Dezii, C., et al. (2002). Coronary heart disease (CHD) in HIV-infected individuals: Associations with antiretroviral therapy [abstract 54]. Antiviral Therapy, 7, L37.
11. Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group (2003). Combination antiretroviral therapy and the risk of myocardial infarction [erratum New England Journal of Medicine, 350, 955]. New England Journal of Medicine, 349, 1993-2003.
12. Decker, C.J., Laitinen, L.M., Bridson, G.W., Raybuck, S.A., Tung, R.D., & Chaturvedi, P.R. (1998). Metabolism of amprenavir in liver microsomes: Role of CYP3A4 inhibition for drug interactions. Journal of Pharmaceutical Sciences, 87, 803-807.
13. Doser, N., Sudre, P., Telenti, A., Wietlisbach, V., Nicod, P., Darioli, R., et al. (2001). Persistent dyslipidemia in HIV-infected individuals switched from a protease inhibitor-containing to an efavirenz-containing regimen. Journal of Acquired Immune Deficiency Syndrome, 26, 389-390.
14. Dubé, M.P., Stein, J.H., Aberg, J.A., Fichtenbaum, C.J., Gerber, J.G., Tashima, K.T., et al., for the Adult AIDS Clinical Trials Group Cardiovascular Subcommittee (2003). Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: Recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clinical Infectious Diseases, 37, 613-627.
15. Duncombe, C., Bloch, M., Austin, D., & Quan, D. (1999). Reversal of hyperlipidaemia and lipodystrophy in patients switching therapy to nelfinavir [abstract 12287]. Bridging the Gap: 12th World AIDS Conference, Geneva, Switzerland, 29 June 1998
16. Eagling, V.A., Back, D.J., & Barry, M.G. (1997). Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. British Journal of Clinical Pharmacology, 44, 190-194.
17. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (2001). Executive summary of the third report of the national cholesterol education program (NCEP) (Adult Treatment Panel III). Journal of the American Medical Association, 285, 2486-2497.
18. Fichtenbaum, C.J., & Gerber, J.G. (2002a). Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clinical Pharmacokinetics, 41, 1195-1211.
19. Fichtenbaum, C.J., Gerber, J.G., Rosenkranz, S.L., Segal, Y., Aberg, J.A., Blaschke, T., et al. and the NIAID AIDS Clinical Trials Group (2002b). Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS, 16, 569-577.
20. Friis-Moller, N., Sabin, C.A., Weber, R., D'Arminio, M.A., el Sadr, W.M., Reiss, P., et al. (2003a). Combination antiretroviral therapy and the risk of myocardial infarction. New England Journal of Medicine, 349, 1993-2003.
21. Friis-Moller, N., Weber, R., Reiss, P., Thiebaut, R., Kirk, O., d'Arminio, M.A., et al. (2003b). Cardiovascular disease risk factors in HIV patients' association with antiretroviral therapy. Results from the DAD study. AIDS, 17, 1179-1193.
22. Garg, A., & Grundy, S.M. (1990). Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. Journal of the American Medical Association, 264, 723-726.
23. Green, M.L. (2002). Evaluation and management of dyslipidemia in patients with HIV infection. Journal of General Internal Medicine, 17, 797-810.
24. Grunfeld, C., Kotler, D.P., Hamadeh, R., Tierney, A., Wang, J., & Pierson, R.N. (1989). Hypertriglyceridemia in the acquired immunodeficiency syndrome. American Journal of Medicine, 86, 27-31.
25. Grunfeld, C., Pang, M., Doerrler, W., Shigenaga, J.K., Jensen, P., & Feingold, K.R. (1992). Lipids, lipoproteins, triglyceride clearance and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Journal of Clinical Endocrinology and Metabolism, 74, 1045-1052.
26. Haas, D.W., Zala, C., Schradar, S., Piliero, P., Jaeger, H., Nunes, D., et al. (2003). Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: A randomized comparative pilot trial. AIDS, 17, 1339-1349.
27. Henry, K., Melroe, H., Huebesch, J., Hermundson, J., & Simpson, J. (1998). Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet, 352, 1031-1032.
28. Holmberg, S.D., Moorman, A.C., Williamson, J.M., Tong, T.C., Ward, D.J., Wood, K.C., et al. & the HIV Outpatient Study (HOPS) Investigators (2002). Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet, 360, 1747-1748.
29. Hsyu, P.H., Schultz-Smith, M.D., Lillibridge, J.H., Lewis, R.H., & Kerr, B.M. (2001). Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrobial Agents and Chemotherapy, 45, 3445-3450.
30. Klein, D., & Hurley, L. (2003). Hospitalizations for coronary heart disease and myocardial infarction among men with HIV-1 infection: Additional follow-up [abstract 747]. Available at: http://www.retroconference.org/2003/ Abstract/Abstract.aspx?AbstractID=2184
31. Knopp, R.H. (1999). Drug treatment of lipid disorders. New England Journal of Medicine, 341, 498-511.
32. Kumar, P., Rodriguez-French, A., Thompson, M., Tashima, K., Williams, V., Wannamaker, P., et al. (2002). Prospective study of hyperlipidemia in ART-naïve subjects taking combivir/abacavir (COM/ABC), COM/nelfinavir (NFV) or stavudine (d4T)/lamivudine (3TC)/NFV (ESS40002) [abstract 33]. Available at: http://www.retroconference.org/2002/Abstract/13081.htm
33. Manfredi, R., & Chiodo, F. (2001). Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: Frequency, relationship with administered drugs and role of hypolipidaemic therapy with bezafibrate. Journal of Infection, 42, 181-188.
34. Martínez, E., Arnaiz, J.A., Podzamczer, D., Dalmau, D., Ribera, E., Domingo, P., et al. for the Nevirapine, Efavirenz and Abacavir (NEFA) Study Team (2003). Substitution of nevirapine, efavirenz or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. New England Journal of Medicine, 349, 1036-1046.
35. Martínez, E., Conget, I., Lozano, L., Casamitjana, R., & Gatell, J.M. (1999). Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS, 13, 805-810.
36. Mary-Krause, M., Cotte, L., Simon, A., Partisani, M. & Costagliola, D., & the Clinical Epidemiology Group from the French Hospital Database (2003). Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS, 17, 2479-2486.
37. Meienberg, F., Battegay, E., Bucher, H.C., & Battegay, M. (2001). The use of lipid-lowering agents in HIV-infected patients. Journal of HIV Therapy, 6, 40-44.
38. Meng, Q., Lima, J.A., Lai, H., Vlahov, D., Celentano, D.D., Strathdee, S., et al. (2002). Use of HIV protease inhibitors is associated with left ventricular morphologic changes and diastolic dysfunction. Journal of Acquired Immune Deficiency Syndrome, 30, 306-310.
39. Montaner, J.S.G. (2000). A novel use of abacavir to simplify therapy and reduce toxicity in PI experienced patients successfully treated with HAART: 48-week results (CNA30017) [abstract 477]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 17-20 September. Herndon, VA: ASM Press.
40. Moore, R.D., Keruly, J.C., & Lucas, G. (2003). Increasing incidence of cardiovascular disease in HIV-infected persons in care [abstract 132]. Available at: http://www.retroconference.org/2003/Abstract/Abstract.aspx? AbstractID=217
41. Moyle, G.J., Lloyd, M., Reynolds, B., Baldwin, C., Mandalia, S., & Gazzard, B.G. (2001). Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS, 15, 1503-1508.
42. Murphy, R.L., & Smith, W.J. (2002). Switch studies: A review. HIV Medicine, 3, 146-155.
43. Murphy, R.L., Pokrovsky, V., Rozenbaum, W., Wood, R., Percival, L., Odeshoo, L., et al. (2003a). Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or ATV: 108-week results of BMS Study 008/044 [abstract and poster 555]. Available at: http://www.retroconference.org/2003/Abstract/Abstract.aspx?AbstractID=2075
44. Murphy, R.L., Sanne, I., Cahn, P., Phanupak, P., Percival, L., Kelleher, T., et al. (2003b). Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naïve subjects: 48-week results. AIDS, 17, 2603-2614.
45. Opravil, M., Hirschel, B., Lazzarin, A., Furrer, H., Chave, J.P., Yerly, S., et al. (2002). A randomized trial of simplified maintenance therapy with abacavir, lamivudine and zidovudine in human immunodeficiency virus infection. Journal of Infectious Diseases, 185, 1251-1260.
46. Panel on Clinical Practices for Treatment of HIV Infection (2004). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [updated 23 March 2004]. Available at: http://aidsinfo.nih.gov/ guidelines/adult/AA_032304.pdf
47. Périard, D., Telenti, A., Sudre, P., Cheseaux, J.J., Halfon, P., Reymond, M.J., et al., for the Swiss HIV Cohort Study (1999). Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation, 100, 700-705.
48. Piscitelli, S.C., & Gallicano, K.D. (2001). Interactions among drugs for HIV and opportunistic infections. New England Journal of Medicine, 344, 984-996.
49. Purnell, J.Q., Zambon, A., Knopp, R.H., Pizzuti, D.J., Achari, R., Leonard, J.M., et al. (2000). Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS, 14, 51-57.
50. Rickerts, V., Brodt, H.R., Staszewski, S., & Stille, W. (2000). Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: The Frankfurt HIV-cohort study. European Journal of Medical Research, 5, 329-333.
51. Riddler, S.A., Smit, E., Cole, S.R., Li, R., Chmiel, J.S., Dobs, A., et al. (2003). Impact of HIV infection and HAART on serum lipids in men. Journal of the American Medical Association, 289, 2978-2982.
52. Ruiz, L., Negredo, E., Domingo, P., Paredes, R., Francia, E., Balague, M., et al. (2001). Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: One-year prospective follow-up of a multicenter, randomized, controlled study. Journal of Acquired Immune Deficiency Syndrome, 27, 229-236.
53. Saag, M.S., Powderly, W.G., Schambelan, M., Benson, C.A., Carr, A., Cirrier, J.S., et al. (2002). Switching antiretroviral drugs for treatment of metabolic complications in HIV-1 infection: Summary of selected trials. Topics in HIV Medicine, 10, 47-51.
54. Sanne, I., Piliero, P., Squires, K., Thiry, A., & Schnittman, S., for the AI424-007 Clinical Trial Group (2003). Results of a phase 2 clinical trial at 48 weeks (AI424-007): A dose-ranging safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naïve subjects. Journal of Acquired Immune Deficiency Syndrome, 32, 18-29.
55. Schaefer, E.J., McNamara, J.R., Genest, J., Jr., & Ordovas, J.M. (1988). Clinical significance of hypertriglyceridemia. Seminars in Thrombosis and Hemostasis, 14, 143-148.
56. Schambelan, M., Benson, C.A., Carr, A., Cirrier, J.S., Dubé, M.P., Gerber, J.G., et al. (2002). Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: Recommendations of an International AIDS Society - USA panel. Journal of Acquired Immune Deficiency Syndrome, 31, 257-275.
57. Shor-Posner, G., Basit, A., Lu, Y., Cabrejos, C., Chang, J., Fletcher, M., et al. (1993). Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. American Journal of Medicine, 94, 515-520.
58. Staszewski, S., Gallant, J.E., Pozniak, A.L., Suleiman, J.M.A.H., Dejesus, E., Lu, B., et al. (2003). Favorable metabolic profile for tenofovir disoproxil fumarate (TDF) versus stavudine (d4T) when used in combination with lamivudine and efavirenz in antiretroviral naïve patients: 96-week interim results [abstract 562]. 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, France.
59. Tobert, J.A. (1988). Efficacy and long-term adverse effect pattern of lovastatin. American Journal of Cardiology, 62, 28J-34J.
60. Transon, C., Leemann, T., & Dayer, P. (1996). In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. European Journal of Clinical Pharmacology, 50, 209-215.
61. Van der Valk, M., Kastelein, J.J., Murphy, R.L., Van Leth, F., Katlama, C., Horban, A., et al., on behalf of the Atlantic Study Team (2001). Nevirapine-containing antiretroviral therapy in HIV-1 infected patients' results in an anti-atherogenic lipid profile. AIDS, 15, 2407-2414.
62. Van Leth, F., Phanuphak, P., Gazzard, B., Cahn, P., Wood, R., Bloch, M., et al., (2003). Lipid changes in a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine (2NN Study) [abstract 97]. Available at: http://www.retroconference.org/2003/ Abstract/Abstract.aspx?AbstractID=97
63. Voorman, R.L., Maio, S.M., Hauer, M.J., Sanders, P.E., Payne, N.A., & Ackland, M.J. (1998). Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: Probable involvement of CYP2D6 and CYP3A. Drug Metabolism and Disposition, 26, 631-639.
64. Walli, R., Michl, G.M., Bogner, J.R., & Goebel, F.D. (2001). Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir. European Journal of Medical Research, 6, 413-421.
65. Williams, D., & Feely, J. (2002). Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clinical Pharmacokinetics, 41, 343-370.
66. Zangerle, R., Sarcletti, M., Gallati, H., Reibnegger, G., Wachter, H., & Fuchs, D. (1994). Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation. Journal of Acquired Immune Deficiency Syndrome, 7, 1149-1156.